Beta Bionics to Present at the Bank of America Securities Health Care Conference
Beta Bionics (BBNX), a company focused on diabetes management solutions, has announced its participation in the upcoming Bank of America Securities Health Care Conference. The presentation is scheduled for Tuesday, May 13, 2025, at 12:35 PM ET (9:35 AM PT) in Las Vegas. Interested parties can access the live audio webcast through the company's investor relations website under the "Events & Presentations" section at investors.betabionics.com. The presentation recording will be archived on the website for future viewing.
Beta Bionics (BBNX), un'azienda specializzata in soluzioni per la gestione del diabete, ha annunciato la sua partecipazione al prossimo Bank of America Securities Health Care Conference. La presentazione è fissata per martedì 13 maggio 2025 alle 12:35 ET (9:35 PT) a Las Vegas. Gli interessati potranno seguire la diretta audio in streaming tramite il sito web delle relazioni con gli investitori della società, nella sezione "Eventi e Presentazioni" all'indirizzo investors.betabionics.com. La registrazione della presentazione sarà inoltre disponibile in archivio sul sito per la visione successiva.
Beta Bionics (BBNX), una empresa centrada en soluciones para el manejo de la diabetes, ha anunciado su participación en la próxima Conferencia de Salud de Bank of America Securities. La presentación está programada para el martes 13 de mayo de 2025 a las 12:35 PM ET (9:35 AM PT) en Las Vegas. Los interesados podrán acceder a la transmisión de audio en vivo a través del sitio web de relaciones con inversionistas de la empresa, en la sección "Eventos y Presentaciones" en investors.betabionics.com. La grabación de la presentación quedará archivada en el sitio para su visualización posterior.
Beta Bionics (BBNX)는 당뇨병 관리 솔루션에 집중하는 회사로, 다가오는 Bank of America Securities 헬스케어 컨퍼런스에 참여할 것이라고 발표했습니다. 발표는 2025년 5월 13일 화요일 오후 12:35 ET (오전 9:35 PT) 라스베이거스에서 예정되어 있습니다. 관심 있는 분들은 회사 투자자 관계 웹사이트의 "이벤트 및 발표" 섹션에서 실시간 오디오 웹캐스트를 시청할 수 있습니다(investors.betabionics.com). 발표 녹화본은 웹사이트에 저장되어 이후에도 시청 가능합니다.
Beta Bionics (BBNX), une entreprise spécialisée dans les solutions de gestion du diabète, a annoncé sa participation à la prochaine Bank of America Securities Health Care Conference. La présentation est prévue pour le mardi 13 mai 2025 à 12h35 ET (9h35 PT) à Las Vegas. Les personnes intéressées pourront accéder à la diffusion audio en direct via le site web des relations investisseurs de la société, dans la section "Événements et Présentations" sur investors.betabionics.com. L'enregistrement de la présentation sera archivé sur le site pour une consultation ultérieure.
Beta Bionics (BBNX), ein Unternehmen, das sich auf Lösungen im Diabetesmanagement spezialisiert hat, hat seine Teilnahme an der bevorstehenden Bank of America Securities Health Care Conference angekündigt. Die Präsentation ist für Dienstag, den 13. Mai 2025, um 12:35 Uhr ET (9:35 Uhr PT) in Las Vegas geplant. Interessierte können den Live-Audio-Webcast über die Investor-Relations-Website des Unternehmens im Bereich "Events & Presentations" unter investors.betabionics.com verfolgen. Die Aufzeichnung der Präsentation wird auf der Website archiviert und steht für eine spätere Ansicht zur Verfügung.
- None.
- None.
IRVINE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that management will present at the Bank of America Securities Health Care Conference in Las Vegas on Tuesday, May 13, 2025 at 12:35 pm Eastern Time (9:35 am Pacific Time).
A live audio webcast of the presentation will be available on the Company’s website in the “Investors—Events & Presentations” section at https://investors.betabionics.com, and will be archived there for future replay following the event.
About Beta Bionics
Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development, and commercialization of innovative solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing advanced adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The iLet Bionic Pancreas is the first FDA-cleared insulin delivery device that autonomously determines every insulin dose and offers the potential to substantially improve overall outcomes across broad populations of PWD. To learn more, visit www.betabionics.com.
Investor Relations:
Blake Beber
Head of Investor Relations
ir@betabionics.com
Media and Public Relations:
Karen Hynes
Vice President of Marketing
media@betabionics.com
Source: Beta Bionics, Inc.
FAQ
When is Beta Bionics (BBNX) presenting at the Bank of America Securities Health Care Conference?
Where can I watch Beta Bionics' (BBNX) Bank of America Securities conference presentation?
Will Beta Bionics' (BBNX) Bank of America Securities conference presentation be available for replay?
Where is the Bank of America Securities Health Care Conference being held in 2025?
